Axsome Therapeutics (AXSM) Total Liabilities (2015 - 2026)

Axsome Therapeutics has reported Total Liabilities for 12 years, with the latest figure at $659.0 million in Q1 2026.

• Quarterly Total Liabilities rose 21.26% year-over-year to $659.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $659.0 million (up 21.26% YoY) and the FY2025 annual result came in at $601.5 million, up 17.6% from the prior year.
• Total Liabilities advanced to $659.0 million in Q1 2026 per AXSM's latest filing, from $601.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $659.0 million in Q1 2026 and troughed at $73.9 million in Q1 2022.
• A 5-year average of $398.5 million and a median of $401.7 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities grew 4.6% in 2022, then surged 275.52% in 2023.
• Over 5 years, Total Liabilities stood at $221.9 million in 2022, then soared by 79.01% to $397.3 million in 2023, then grew by 28.75% to $511.5 million in 2024, then grew by 17.6% to $601.5 million in 2025, then climbed by 9.56% to $659.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $659.0 million, $601.5 million, and $595.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.